Erasca (ERAS) EBIT (2020 - 2026)
Erasca (ERAS) reported EBIT of -$187.9 million for Q1 2026, down 427.4% on a YoY basis from $57.4 million in Q1 2025, and down 476.34% quarter-over-quarter from -$32.6 million in Q4 2025.
Erasca (ERAS) EBIT (2020 - 2026) Analysis & Trends
Erasca has reported EBIT for 7 years, with the latest figure at -$187.9 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT fell 427.4% year-over-year to -$187.9 million; the trailing twelve-month figure through Mar 2026 stood at -$293.2 million (down 66.24% YoY), and the FY2025 full-year result was -$140.9 million, up 21.54% from the prior year.
- EBIT for Q1 2026 stood at -$187.9 million, down from -$32.6 million in the prior quarter.
- The five-year high for EBIT was -$32.6 million in Q4 2025, with the low at -$187.9 million in Q1 2026.
- Historically, EBIT has averaged -$52.8 million across 5 years, with a median of -$36.5 million in 2022.
- Annual changes were most pronounced in 2023 — EBIT jumped 75.47% — and 2026, when it plunged 427.4%.
- Erasca's EBIT stood at -$138.1 million in 2022, then jumped by 75.47% to -$33.9 million in 2023, then fell by 5.43% to -$35.7 million in 2024, then increased by 8.7% to -$32.6 million in 2025, then plunged by 476.34% to -$187.9 million in 2026.
- The last three EBIT figures came in at -$187.9 million (Q1 2026), -$32.6 million (Q4 2025), and -$34.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | -187.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -187.91 Mn |
| Dec 31, 2025 | -32.60 Mn |
| Sep 30, 2025 | -34.55 Mn |
| Jun 30, 2025 | -38.13 Mn |
| Mar 31, 2025 | -35.63 Mn |
| Dec 31, 2024 | -35.71 Mn |
| Sep 30, 2024 | -37.24 Mn |
| Jun 30, 2024 | -67.78 Mn |
| Mar 31, 2024 | -38.85 Mn |
| Dec 31, 2023 | -33.87 Mn |
| Sep 30, 2023 | -34.66 Mn |
| Jun 30, 2023 | -35.97 Mn |
| Mar 31, 2023 | -37.03 Mn |
| Dec 31, 2022 | -138.08 Mn |
| Sep 30, 2022 | -36.96 Mn |
| Jun 30, 2022 | -35.91 Mn |
| Mar 31, 2022 | -36.51 Mn |
| Dec 31, 2021 | -31.05 Mn |
| Sep 30, 2021 | -46.04 Mn |
| Jun 30, 2021 | -28.18 Mn |